We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA ORDERS PRIMAPHARM TO STOP HYDRASE ADS

FDA ORDERS PRIMAPHARM TO STOP HYDRASE ADS

July 3, 2006

The FDA is ordering California-based PrimaPharm to stop advertisements of its drug Hydase, saying that the ads are misleading because the company fails to communicate risks associated with the product.

The agency's Division of Drug Marketing, Advertising and Communications (DDMAC) wrote in its June 29 letter that the company's incomplete advertisement for Hydase (hyaluronidase injection) violates the Federal Food, Drug, and Cosmetic Act. The agency is ordering PrimaPharm to "immediately cease" the use of this ad. DDMAC also wants the company to provide a comprehensive plan of action for disseminating a more accurate ad. The agency wants a response to the letter by July 14.

"The sales aids raise public health and safety concerns through their complete omission of risk information for Hydase by suggesting Hydase is safer than has been demonstrated," the letter said. The materials are supposed to include the warnings in the FDA-approved product labeling, stating that the drug should not be injected into or around an infected or acutely inflamed area, should not be used to reduce the swelling of bites or stings and should not be applied directly to the cornea.

Hydase is an adjuvant, used to increase the absorption and dispersion of other injected drugs, to improve resorption of radiopaque agents, and for hypodermclysis.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing